Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (395) clinical trials

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Subjects will be randomized using a 2:1 treatment allocation (i.e. two-thirds of the subjects will receive PV-10). Subjects in the comparator arm who have completed at least 1 cycle of study treatment and who meet the study protocol definition of disease progression but do not have evidence of visceral metastases ...

Phase

Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases

Study Drug Administration: If you are found to be eligible to take part in this study, you will receive atezolizumab by vein over 30-60 minutes (+/-10-15 minutes). Bevacizumab will then be given by vein over 30, 60, or 90 minutes (+/-10-15 minutes). You may be given standard drugs to help ...

Phase

Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases

Study Procedure: You will receive SRS on Day 1. There will be 1 day of treatment. You will sign a separate consent form for SRS that will explain the procedure and risks in detail. Study Visits: At 1, 6, and 9 months (+/- 14 days) after Day 1, the following ...

Phase

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Primary Objective: To determine the irRECIST* response rate of pembrolizumab with ipilimumab following initial progression or stable disease to anti-PD1/L1 antibody (or combination not containing anti-CTLA4) in subjects with advanced melanoma. Secondary Objective To summarize the progression-free survival (RECIST v1.1 and irRC) of the combination following prior treatment with anti-PD1/L1 ...

Phase

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 4 groups of 3 participants will be enrolled in Part 1, and up to 20 participants will be ...

Phase

Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab, vemurafenib and cobimetinib will ...

Phase

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma Merkel Cell Carcinoma or Other Solid Tumors

The purpose of this phase II clinical study is to test the good and bad effects of T-VEC (talimogene laherparepvec) with or without hypofractionated radiotherapy on people with melanoma, Merkel cell carcinoma, or other solid tumors with skin metastasis.

Phase

Study of HBI-8000 With Nivolumab in Melanoma Renal Cell Carcinoma and Non-Small Cell Lung Cancer

A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC). The primary objective of this study is: -To evaluate the safety and tolerability of HBI-8000 when ...

Phase

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

This is a multicenter, open-label, phase 1 study that is being done to test intratumoral injections of TTI-621 in patients that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts: Dose Escalation and Dose Expansion. During the escalation part ...

Phase

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies. Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once ...

Phase